Compare Recursion Pharmaceuticals Inc (RXRX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Veritone Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Veritone Inc trades at $1.12 (market cap $97.60M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 15.7× Veritone Inc's market cap. Which is the better fit depends on your goals.
| RXRX | VERI | |
|---|---|---|
Market Cap | $1.53B | $97.60M |
Sector | Health | Technology |
52-Week High | $6.79 | $8.39 |
52-Week Low | $2.84 | $1.02 |
Enterprise Value | $946.50M | $129.63M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
VERI trades at $1.05, up 2.94% on the day, but remains in a bearish technical trend. The company reported a net loss of $111.73 million in 2025, with a negative net income margin of -123.76%, while revenue declined to $92.19 million. Multiple securities class action lawsuits, with a July 20, 2026 deadline, highlight significant legal and reputational risks stemming from alleged improper revenue accounting.
The outlook is highly speculative given severe profitability challenges and ongoing litigation. Analyst consensus is split between Buy and Hold, but fundamental weaknesses and legal overhangs present substantial downside risk. Investment suitability is limited to risk-tolerant investors monitoring resolution of legal issues and a path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
